Cargando…
Tildacerfont for the Treatment of Patients With Classic Congenital Adrenal Hyperplasia: Results From a 12-Week Phase 2 Clinical Trial in Adults With Classic CAH
Background: Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21-OHD) is an autosomal recessive disorder characterized by insufficient cortisol production resulting in excess adrenocorticotropic hormone (ACTH) and adrenal androgen production. Standard-of-care therapy with glucoc...
Autores principales: | Auchus, Richard Joseph, Merke, Deborah P, Madu, Ivy-Joan, Nakhle, Samer, Sarafoglou, Kyriakie, Huang, Michael, Moriarty, David, Barnes, Chris, Newfield, Ron S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8090554/ http://dx.doi.org/10.1210/jendso/bvab048.1011 |
Ejemplares similares
-
Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies
por: Sarafoglou, Kyriakie, et al.
Publicado: (2021) -
Assessment of Steroid Hormones in Both Saliva and Blood During a Phase 2 Clinical Trial for the Use of Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia
por: Keevil, Brian, et al.
Publicado: (2021) -
OR18-4 Crinecerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, Lowers Adrenal Androgens and Precursors in Adolescents with Classic Congenital Adrenal Hyperplasia
por: Auchus, Richard, et al.
Publicado: (2022) -
Hyperthermia as a Steroidogenic Inhibitor of Adrenodortical Cells, an Adrenal Sparing Treatment for Primary Aldosteronism?
por: Donlon, Padraig T, et al.
Publicado: (2021) -
MON-035 Aldosterone Secretion in a Human Adrenal Cell Line Is Enhanced by the Endocrine-Disrupting Chemical Di-(2-Ethylhexyl) Phthalate (DEHP)
por: Schupbach, Chad, et al.
Publicado: (2019)